Lini Pandite

1.2k total citations · 1 hit paper
9 papers, 565 citations indexed

About

Lini Pandite is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Genetics. According to data from OpenAlex, Lini Pandite has authored 9 papers receiving a total of 565 indexed citations (citations by other indexed papers that have themselves been cited), including 7 papers in Oncology, 6 papers in Pulmonary and Respiratory Medicine and 4 papers in Genetics. Recurrent topics in Lini Pandite's work include HER2/EGFR in Cancer Research (4 papers), Chronic Lymphocytic Leukemia Research (4 papers) and Lung Cancer Treatments and Mutations (4 papers). Lini Pandite is often cited by papers focused on HER2/EGFR in Cancer Research (4 papers), Chronic Lymphocytic Leukemia Research (4 papers) and Lung Cancer Treatments and Mutations (4 papers). Lini Pandite collaborates with scholars based in United States, Netherlands and United Kingdom. Lini Pandite's co-authors include Tae Min Kim, Pierre‐Jean Souquet, Harry J.M. Groen, Julien Mazières, Élisabeth Quoix, Bo Ma, Egbert F. Smit, Anthony M. D’Amelio, David Planchard and Byoung Chul Cho and has published in prestigious journals such as Journal of Clinical Oncology, The Lancet Oncology and Breast Cancer Research and Treatment.

In The Last Decade

Lini Pandite

9 papers receiving 552 citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Dabrafenib in patients with BRAFV600E-positive advanced non-small-cell lung cancer: a single-arm, multicentre, open-label, phase 2 trial

2016 334 citations David Planchard, Tae Min Kim et al. The Lancet Oncology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Lini Pandite United States	8	385	318	243	118	76	9	565
Lucia Trandafir Switzerland	11	247 0.6×	272 0.9×	280 1.2×	85 0.7×	61 0.8×	22	634
Graham Temple United Kingdom	12	441 1.1×	431 1.4×	288 1.2×	84 0.7×	82 1.1×	17	721
Max Hallin United States	6	276 0.7×	260 0.8×	362 1.5×	142 1.2×	56 0.7×	6	632
Samuel Tracy United States	7	273 0.7×	301 0.9×	245 1.0×	126 1.1×	123 1.6×	15	495
Feng-yi Feng China	8	450 1.2×	345 1.1×	177 0.7×	58 0.5×	81 1.1×	35	673
S. Johnston United Kingdom	9	433 1.1×	231 0.7×	341 1.4×	332 2.8×	108 1.4×	17	783
Edna Chow‐Maneval United States	14	458 1.2×	478 1.5×	231 1.0×	183 1.6×	80 1.1×	24	724
James A. Onori United States	4	224 0.6×	236 0.7×	254 1.0×	123 1.0×	46 0.6×	5	500
José Rodrigues Pereira Brazil	9	541 1.4×	622 2.0×	419 1.7×	166 1.4×	85 1.1×	16	915
Greg J. Riely United States	7	557 1.4×	664 2.1×	353 1.5×	152 1.3×	64 0.8×	13	798

Countries citing papers authored by Lini Pandite

Since Specialization

Citations

This map shows the geographic impact of Lini Pandite's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Lini Pandite with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Lini Pandite more than expected).

Fields of papers citing papers by Lini Pandite

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Lini Pandite. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Lini Pandite. The network helps show where Lini Pandite may publish in the future.

Co-authorship network of co-authors of Lini Pandite

This figure shows the co-authorship network connecting the top 25 collaborators of Lini Pandite. A scholar is included among the top collaborators of Lini Pandite based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Lini Pandite. Lini Pandite is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

9 of 9 papers shown

Diaz, Jose, Cora N. Sternberg, Faisal Mehmud, et al.. (2016). Overall Survival Endpoint in Oncology Clinical Trials: Addressing the Effect of Crossover - The Case of Pazopanib in Advanced Renal Cell Carcinoma. Oncology. 90(3). 119–126. 9 indexed citations

Planchard, David, Tae Min Kim, Julien Mazières, et al.. (2016). Dabrafenib in patients with BRAFV600E-positive advanced non-small-cell lung cancer: a single-arm, multicentre, open-label, phase 2 trial. The Lancet Oncology. 17(5). 642–650. 334 indexed citations breakdown →

Johnston, Stephen, Henry Gómez, Salomon M. Stemmer, et al.. (2013). A randomized and open-label trial evaluating the addition of pazopanib to lapatinib as first-line therapy in patients with HER2-positive advanced breast cancer. Breast Cancer Research and Treatment. 137(3). 755–766. 33 indexed citations

Storniolo, Anna Maria, Mark D. Pegram, Beth Overmoyer, et al.. (2008). Phase I Dose Escalation and Pharmacokinetic Study of Lapatinib in Combination With Trastuzumab in Patients With Advanced ErbB2-Positive Breast Cancer. Journal of Clinical Oncology. 26(20). 3317–3323. 89 indexed citations

Chu, Quincy S., Garry Schwartz, Johann S. de Bono, et al.. (2007). Phase I and Pharmacokinetic Study of Lapatinib in Combination With Capecitabine in Patients With Advanced Solid Malignancies. Journal of Clinical Oncology. 25(24). 3753–3758. 48 indexed citations

Savage, S., Jaap Verweij, F. Eskens, et al.. (2006). A phase I, open-label study of the safety and pharmacokinetics (PK) of pazopanib (P) and lapatinib (L) administered concurrently. Journal of Clinical Oncology. 24(18_suppl). 3088–3088. 21 indexed citations

Suttle, A. Benjamin, et al.. (2004). Pharmacokinetics (PK) and tolerability of GW786034, a VEGFR tyrosine kinase inhibitor, after daily oral administration to patients with solid tumors. Journal of Clinical Oncology. 22(14_suppl). 3054–3054. 20 indexed citations

Westermann, Anneke M., M. Versola, Kevin M. Koch, et al.. (2004). Phase I trial to determine the safety and tolerability of GW572016 in combination with oxaliplatin (OX)/5-fluorouracil (5-FU)/leucovorin (LV) [FOLFOX4] in patients with solid tumors. Journal of Clinical Oncology. 22(14_suppl). 2044–2044. 7 indexed citations

Beijnen, J. H., Anneke M. Westermann, M. Versola, et al.. (2004). Phase I trial to determine the safety and tolerability of GW572016 in combination with oxaliplatin (OX)/5-fluorouracil (5-FU)/leucovorin (LV) [FOLFOX4] in patients with solid tumors. Journal of Clinical Oncology. 22(14_suppl). 2044–2044. 4 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact